LRP5/6 are infrequently mutated in primary (≤0.61%) and metastatic (≤2.1%) prostate cancer, and are predominantly missense variants (Table 1 and Tables S1–S4) [64,65,66]. Here, LRP5 is linked to prostate cancer.